Proteus Infections Treatment & Management
- Author: Gus Gonzalez, MD; Chief Editor: Michael Stuart Bronze, MD more...
Recommended empirical treatment includes the following:
- Uncomplicated UTIs in women can be treated on an outpatient basis with an oral quinolone for 3 days or trimethoprim/sulfamethoxazole (TMP/SMZ) for 3 days.
- Acute uncomplicated pyelonephritis in women can be treated with oral quinolones for 7-14 days, single-dose ceftriaxone or gentamicin followed by TMP/SMZ, or an oral cephalosporin or quinolone for 14 days as outpatient therapy. For hospitalized patients, therapy consists of parenteral (or oral once the oral route is available) ceftriaxone, quinolone, gentamicin (plus ampicillin), or aztreonam until defervescence. Then, an oral quinolone, cephalosporin, or TMP/SMZ for 14 days may be added to complete treatment.
- Complicated UTIs in men and women can be treated with a 10- to 21-day course of oral therapy (in the same manner as for hospitalized patients) as long as the follow-up is adequate.
If struvite renal calculus is associated with Proteus infection, it must be removed.
Most nonurologic infections result in abscesses. Radical surgical debridement is the cornerstone of successful therapy. Amputation may be necessary if skin or muscle necrosis of an extremity is the presenting infection, but tissue recovery is often better than expected. Broad-spectrum antimicrobial therapy is started empirically and is modified by the results of smears and cultures. Mortality and morbidity rates are high, even with adequate treatment.
The discovery of stones requires an evaluation by a physician knowledgeable in the short- and long-term management of stones, typically a urologist or nephrologist.
Luzzaro F, Brigante G, D'Andrea MM, Pini B, Giani T, Mantengoli E, et al. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management. Int J Antimicrob Agents. 2009 Apr. 33(4):328-33. [Medline].
Lewis JS 2nd, Herrera M, Wickes B, Patterson JE, Jorgensen JH. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother. 2007 Nov. 51(11):4015-21. [Medline].
Wang JT, Chen PC, Chang SC, Shiau YR, Wang HY, Lai JF, et al. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program. BMC Infect Dis. 2014 Sep 5. 14:486. [Medline]. [Full Text].
Helmy MM, Wasfi R. Phenotypic and molecular characterization of plasmid mediated AmpC ß-lactamases among Escherichia coli, Klebsiella spp., and Proteus mirabilis isolated from urinary tract infections in Egyptian hospitals. Biomed Res Int. 2014. 2014:171548. [Medline]. [Full Text].
Tsai HY, Chen YH, Tang HJ, Huang CC, Liao CH, Chu FY, et al. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum ß-lactamase-producing Proteus mirabilis. Diagn Microbiol Infect Dis. 2014 Jul 26. [Medline].
Williams GJ, Stickler DJ. Effect of triclosan on the formation of crystalline biofilms by mixed communities of urinary tract pathogens on urinary catheters. J Med Microbiol. 2008 Sep. 57:1135-40. [Medline]. [Full Text].
Gaonkar TA, Caraos L, Modak S. Efficacy of a silicone urinary catheter impregnated with chlorhexidine and triclosan against colonization with Proteus mirabilis and other uropathogens. Infect Control Hosp Epidemiol. May 2007. 28:596-8. [Medline].
Beck-Sague C, Villarino E, Giuliano D, et al. Infectious diseases and death among nursing home residents: results of surveillance in 13 nursing homes. Infect Control Hosp Epidemiol. 1994 Jul. 15(7):494-6. [Medline].
Braunwald E, Fauci AS, Kasper DL. Harrison's Principles of Internal Medicine. 15th ed. New York, NY: McGraw Hill, Inc; 2001.
Dembry LM, Andriole VT. Renal and perirenal abscesses. Infect Dis Clin North Am. 1997 Sep. 11(3):663-80. [Medline].
Endimiani A, Luzzaro F, Brigante G, et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2005 Jul. 49(7):2598-605. [Medline].
Engel JD, Schaeffer AJ. Evaluation of and antimicrobial therapy for recurrent urinary tract infections in women. Urol Clin North Am. 1998 Nov. 25(4):685-701, x. [Medline].
Kaye D, Tunkel AR, Fournier GR. Stein, ed. Internal Medicine. 5th ed. St Louis, Mo: Mosby-Year Book; 1998.
Li X, Lockatell CV, Johnson DE, et al. Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis. Infect Immun. 2004 Jan. 72(1):66-75. [Medline].
Lipsky BA. Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis, and treatment. Ann Intern Med. 1989 Jan 15. 110(2):138-50. [Medline].
Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, Pa: Churchill Livingstone; 2000.
Pewitt EB, Schaeffer AJ. Urinary tract infection in urology, including acute and chronic prostatitis. Infect Dis Clin North Am. 1997 Sep. 11(3):623-46. [Medline].
Roberts JA. Management of pyelonephritis and upper urinary tract infections. Urol Clin North Am. 1999 Nov. 26(4):753-63. [Medline].
Schwartz BF, Stoller ML. Nonsurgical management of infection-related renal calculi. Urol Clin North Am. 1999 Nov. 26(4):765-78, viii. [Medline].
Walsh PC, Schaeffer AJ. Walsh PC, Schaeffer AJ, eds. Campbell's Urology. 7th ed. Philadelphia, Pa: WB Saunders; 1997.
Warren JW. Catheter-associated urinary tract infections. Infect Dis Clin North Am. 1997 Sep. 11(3):609-22. [Medline].
Wu YL, Liu KS, Yin XT, Fei RM. GlpC gene is responsible for biofilm formation and defense against phagocytes and imparts tolerance to pH and organic solvents in Proteus vulgaris. Genet Mol Res. 2015 Sep 9. 14 (3):10619-29. [Medline].